May 7, 2019 08:25 AM EDTUpdated 10:50 AM
People
R&D
Pharma

Al­ler­gan chief Saun­ders takes a painful $2.5B hit on an ug­ly PhI­II flop

John Carroll

Editor & Founder

Now that Al­ler­gan chief Brent Saun­ders has stared down the ac­tivists — for now, any­way — the com­pa­ny is back with a $2.5 bil­lion write­down for their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times